Barchart.com's Chart of the Day - Haemonetics
Related Stocks
 HAE - Haemonetics Corp
SymLastChgPct
HAE109.77-0.01-0.01%

TheBarchart Chart of the Daybelongs toHaemonetics (NYSE:HAE). I found the medical products stock by using Barchart to sort theTop 100 Stockswhich are the stocks with the highest Weighted Alpha, first by the most frequent number of new highs in the last month, then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 4/16 the stock gained 17.31%.

Haemonetics Corporation is a Global Leader in Blood Management Solutions. Their comprehensive portfolio of devices, information management, consulting services offers blood management solutions for each facet of the blood supply chain from plasma blood collectors to hospitals. They believe that through proper blood management, their portfolio of products and services helps to prevent a transfusion for the patient who doesn't need one and provides the right blood product, at the right time, in the right dose to the right patient who does.

HAE

Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on theBarchart.comweb site when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 132.40+ Weighted Alpha
  • 110.24% gain in the past year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 13 new highs and up 19.60% in the last month
  • Relative Strength Index 79.83%
  • Technical support level at 86.81
  • Recently traded at 87.69 with a 50 day moving average of 75.83

Fundamental factors:

  • Market Cap $4.67 billion
  • P/E 46.64
  • Revenue expected to grow 1.30% this year and another 4.30% next year
  • Earnings estimated to increase 22.20% this year, an additional 11.80% next year and continue to compound at an annual rtae of 5.00% for the next 5 years
  • Wall Street analysts issued 2 strong buy, 1 buy, 5 hold and 1 under perform recommendation on the stock